Skip to main content
. 2018 Jul 21;172(1):167–177. doi: 10.1007/s10549-018-4890-z

Fig. 2.

Fig. 2

Selection of study participants and non-adherence. Non-adherence was defined as having MPR less than 80% over 5 year of follow-up. ET endocrine treatment, M1 distant metastasis, MPR Medical Possession Ratio, calculated by dividing the total defined daily dose (DDD) required during the period of observation by the total number of dispensed DDD